A profile of the head and neck, with three regions Editorial illustration of a side-profile silhouette of a head and neck rendered in soft watercolour, with three highlighted anatomical zones — oral cavity, oropharynx, and larynx — arranged along the airway. oral cavity tongue, gums, lining oropharynx tonsil, base of tongue larynx voice box, hypopharynx
Oral cavity
Tobacco / gutka-driven
Most common in India. Surgery first, often with radiation.
Oropharynx
HPV-related, rising
Tonsil, base of tongue. Often responds better; de-escalation possible.
Larynx / hypopharynx
Smoking and alcohol-driven
Voice-preserving chemoradiation often preferred over surgery.
Site, cause, and HPV status all shape the treatment plan. Most are squamous cell carcinomas, but they don't all behave alike.

Head & Neck Cancer Treatment in Hyderabad

Reviewed May 2026  ·  Dr. Madhav Danthala

India has one of the highest rates of oral cancer globally — driven mostly by tobacco and gutka. HPV-related throat cancers are also rising. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy for head and neck cancers at KIMS-Sunshine Hospitals, Begumpet, and Peoples Polyclinic, Manikonda.

When to See a Doctor

Most mouth ulcers heal in two weeks. The pattern that matters is anything that does not.

Four warning signs for head and neck cancer Central watercolor circle with four annotated callouts: non-healing mouth ulcer, persistent hoarseness, painless neck lump, white or red patches. Non-healing ulcer Mouth sore lasting more than three weeks, often painless. Persistent hoarseness Voice change lasting more than three weeks — see ENT. Painless neck lump A neck lump that does not resolve, especially if firm. White or red patches Pre-cancerous changes in tobacco users especially. Most ulcers heal in two weeks. Anything that doesn't is what warrants the visit.

Dr. Danthala's Approach

Head and neck cancer treatment requires multidisciplinary coordination. Three principles shape every consultation.

  1. HPV status first

    Every oropharyngeal cancer is tested for HPV at diagnosis — it changes prognosis and may guide de-escalated treatment.

  2. Multidisciplinary planning

    Care is coordinated across head-and-neck surgery, radiation oncology, and medical oncology — with shared decision-making at every step.

  3. Clear, structured communication

    Every consult ends with a written summary of the plan, including expected impact on speech, swallowing, and quality of life.

Treatment Options

Head and neck cancer treatment depends on site, stage, and HPV status. Quality of life — speech, swallowing, appearance — is part of every plan. Below are the major modalities, almost always combined.

Surgery

Resection with reconstruction; TORS for selected oropharyngeal

For oral cavity cancers, surgical resection followed by reconstruction (often with free flaps) is the standard. Neck dissection is usually included to remove nodal disease. Transoral robotic surgery (TORS) has changed the landscape for selected oropharyngeal cancers, allowing minimally invasive resection with preserved function. Elective tracheostomy may be needed for swelling management.

Radiation therapy

IMRT, often concurrent with chemotherapy

Intensity-modulated radiation therapy (IMRT) over 6-7 weeks is foundational, especially for laryngeal preservation. For locally advanced disease, concurrent chemoradiation with cisplatin is the standard. For HPV-positive oropharyngeal cancers, de-escalated radiation protocols are being studied to reduce long-term toxicity. Speech-and-swallowing therapy starts before treatment and continues afterward.

Systemic therapy

Cisplatin, cetuximab, immunotherapy for advanced disease

Cisplatin is the standard radiosensitiser. Cetuximab (anti-EGFR) is an alternative for cisplatin-ineligible patients. For recurrent or metastatic disease, pembrolizumab and nivolumab have changed outcomes — pembrolizumab + chemotherapy is the standard first-line for PD-L1+ disease. EGFR-targeted therapy and clinical trials of HPV-targeted approaches continue to expand the menu.

Multidisciplinary support

Speech, swallowing, dental, nutrition, prosthodontic

Head and neck cancer treatment routinely affects swallowing, speech, taste, and dental health. A multidisciplinary team — speech-language therapists, dietitians, dental oncologists, prosthodontists, and rehabilitation specialists — works alongside surgical, medical, and radiation oncology throughout treatment. Pre-treatment dental work and feeding-tube planning are part of the standard workup.

Treatment is shaped by site, stage, HPV status, and quality-of-life priorities. The list above is the menu. The right plan is built with the patient in the room.

Frequently Asked Questions

What are the warning signs of oral cancer?

Any non-healing mouth ulcer or sore that persists more than three weeks. White or red patches inside the mouth, painless neck lump, persistent hoarseness, difficulty swallowing, or unexplained ear pain on one side are also warning signs.

Does gutka cause oral cancer?

Yes. Gutka, paan, khaini, and other smokeless tobacco products are major causes of oral cancer in India. They cause oral submucous fibrosis that progresses to cancer over years. Stopping use significantly reduces risk.

What is HPV-related oropharyngeal cancer?

Some throat cancers — particularly tonsils and base of tongue — are caused by HPV infection. HPV-positive cancers behave differently from tobacco-related, often respond better to treatment, and may benefit from de-escalated protocols.

Should children get the HPV vaccine?

Yes. Given between ages 9 and 14 (catch-up to 26), the HPV vaccine prevents the strains most strongly linked to cervical, anal, and oropharyngeal cancers. The same vaccine that prevents cervical cancer in women also prevents HPV-related throat cancers in men and women. Tobacco-driven oral and laryngeal cancers share the risk profile of lung cancer — counselling for either should cover both.

What does treatment involve?

Early-stage: surgery or radiation alone. Locally advanced: combined chemoradiation. Recurrent or metastatic: immunotherapy (pembrolizumab, nivolumab) and targeted therapy (cetuximab) plus chemotherapy.

About Dr. Madhav Danthala

Dr. Madhav Danthala is a medical oncologist and hemato-oncologist practising at KIMS-Sunshine Hospitals, Begumpet and Peoples Polyclinic, Manikonda, Hyderabad. His clinical interests span breast, lung, gastrointestinal, gynaecologic, and head & neck cancers, with a focus on subtype-led treatment planning, second opinions, and shared decision-making. He has trained at premier oncology institutes and performed 300+ stem cell transplants.

Read full profile, training, and credentials →

Trusted guidelines & further reading

From our blog

All blog posts →